Press Releases 2015

June 19, 2015
Galapagos raises €4.4 million through warrant exercises
View English version - Bekijk Nederlandse versie

June 18, 2015
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients
View English version - Bekijk Nederlandse versie

 June 15, 2015
AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference
View English version - Bekijk Nederlandse versie

 June 10, 2015
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment
View English version - Bekijk Nederlandse versie

May 26, 2015
Galapagos receives transparency notices
View English version - Bekijk Nederlandse versie

May 19, 2015
Galapagos announces share capital increase
View English version - Bekijk Nederlandse versie

May 19, 2015
Galapagos announces closing of NASDAQ IPO
View English version - Bekijk Nederlandse versie

May 18, 2015
Galapagos announces full exercise of underwriters’ option to purchase additional shares
View English version - Bekijk Nederlandse versie

 May 14, 2015
Galapagos raises $275 million gross proceeds with NASDAQ IPO
View English version - Bekijk Nederlanse versie

May 12, 2015
Galapagos announces size of global offering increased to $250 million
View English version - Bekijk Nederlanse versie

May 7, 2015
Johnson & Johnson Innovation – JJDC, Inc. indicate interest in $25 million worth of shares in Galapagos’ global offering
View English version - Bekijk Nederlanse versie

May 6, 2015
Galapagos announces launch of proposed global offering
View English version - Bekijk Nederlandse versie

May 6, 2015

Galapagos listed 10 years on Euronext Amsterdam and Brussels
View English version - Bekijk Nederlandse versie

 May 1, 2015
Galapagos creates new warrant plan
View English version - Bekijk Nederlandse versie

May 1, 2015
BNP Paribas notify of 4.8% shareholding in Galapagos
View English version - Bekijk Nederlandse versie

April 27, 2015
Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial
View English version - Bekijk Nederlandse versie

April 15, 2015
Galapagos files registration statement in the United States for a proposed global offering
View English version - Bekijk Nederlandse versie

 April 14, 2015
Galapagos’ JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B study in moderate to severe rheumatoid arthritis patients
View English version - Bekijk Nederlandse versie

March 27, 2015
Publication of Annual Report 2014 and invitation to the Annual Shareholders’ Meeting to be held on 28 April 2015
View English version - Bekijk Nederlandse versie

March 27, 2015
Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members invest
View English version - Bekijk Nederlandse versie

March 17, 2015
Galapagos regains rights to GLPG1690,
announces end of alliance with Janssen
View English version - Bekijk Nederlandse versie

March 6, 2015
Galapagos to be included in Amsterdam Midcap Index
View English version - Bekijk Nederlandse versie

 March 6, 2015
Galapagos reports 2014 financial results
View English version - Bekijk Nederlandse versie
View Financial Tables- Bekijk Financiele Tabellen

 February 23, 2015
Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment
View English version - Bekijk Nederlandse versie

 February 16, 2015
Galapagos reports positive Phase 1 results for GLPG1690
View English version - Bekijk Nederlandse versie

  February 11, 2015
Galapagos receives €1.6 million IWT grant for hepatitis B program
View English version - Bekijk Nederlandse versie

February 9, 2015
BNP Paribas notify of 5.08% shareholding in Galapagos
View English version - Bekijk Nederlandse versie

January 22, 2015
Galapagos receives €2.5 million IWT grant for antibiotic research
View English version - Bekijk Nederlandse versie

January 21, 2015
Delta Lloyd notify of 4.96% shareholding in Galapagos
View English version - Bekijk Nederlandse versie

January 9, 2015
Vicki Sato resigns from Galapagos Board
View English version - Bekijk Nederlandse versie

 January 8, 2015
 
Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients
View English version - Bekijk Nederlandse versie

© Copyright 2015 Galapagos NV | Disclaimer | General Purchase Terms 

 
Test